Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

By O. Sitbon, M. Humbert, H. Nunes, F. Parent, G. Garcia, P. Hervé, M. Rainisio, G. Simonneau. Journal of the American College of Cardiology, 2002

1,463 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/83f28f6d374720cc4be4f036b59c4730ada50ea2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. G. Simonneau
2. N. Galiè

Citations in the corpus

• EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) (2009, result): “Based on the results of RCTs and two large long term observational studies, which have documented an improvement in survival of patients with iPAH treated with epoprostenol [56,57], intravenous epoprostenol has been approved by FDA for treatment of severe (WHO class III or IV) PAH.”
• Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. (2007, background): “Reports on the prognostic value of PAP have contradicted each other.(2,3) Sitbon et al.”
• Pulmonary arterial hypertension (2013, background): “Long-term persistence of efficacy has also been shown [201,214] in idiopathic PAH, as well as in other associated PAH [215,216] and in non operable CTEPH [217].”